8 August 2023 - Here we go again: An op-ed column printed in this publication is yet another example of a drug company-focused view on the 340B Drug Pricing Program, couched in the language of reform.

Its criticisms apply a familiar formula. First, start with presenting drug company-funded research as if it is non-biased. Next, use misleading statistics to accuse safety-net providers of abusing the program. After that, offer faux concerns about wanting to protect medically underserved patients.

Read The Hill article